Mdxhealth SA (MDXH) — SEC Filings

Overview

Mdxhealth SA (MDXH) is a publicly traded company tracked on ReadTheFiling. The most recent enriched filing is a 3 filed on Apr 11, 2026: On March 18, 2026, MDxHealth SA filed a Form 3, an initial statement of beneficial ownership of securities. This filing indicates changes in the ownership of securities for individuals or entities associated with the company. The filing was accepted by the SEC on April 10, 2026.

Sentiment Summary

Across 35 filings, the sentiment breakdown is: 2 bullish, 33 neutral. The dominant filing sentiment for Mdxhealth SA is neutral.

Filing Type Overview

Mdxhealth SA (MDXH) has filed 1 3, 1 S-8, 26 6-K, 2 20-F, 3 SC 13G, 1 SC 13D/A, 1 SC 13G/A with the SEC between Jan 2024 to Apr 2026.

Filings by Year

2026 · 2025 · 2024

Recent Filings (35)

• MDxHealth SA Files Initial Ownership Statement — 3 · Apr 11, 2026 Risk: low
  On March 18, 2026, MDxHealth SA filed a Form 3, an initial statement of beneficial ownership of securities. This filing indicates changes in the ownership of se
• S-8 Filing — S-8 · Apr 3, 2026
• MDxHealth SA Files 6-K, Attaches Press Release — 6-K · Nov 12, 2025 Risk: low
  On November 12, 2025, MDxHealth SA issued a press release, attached as Exhibit 99.1 to this 6-K filing. The filing indicates that MDxHealth SA is a foreign priv
• MDxHealth SA Files 6-K, Attaches Press Release — 6-K · Sep 16, 2025 Risk: low
  On September 15, 2025, MDxHealth SA issued a press release attached as Exhibit 99.1 to this 6-K filing. The filing does not contain specific financial figures o
• MDxHealth SA Files 2025 Interim Report on Form 6-K — 6-K · Aug 14, 2025 Risk: low
  MDxHealth SA filed a Form 6-K on August 14, 2025, reporting its 2025 Interim Report. The report includes preliminary financial results and confirms the accuracy
• MDxHealth SA Files Form 6-K with Press Release — 6-K · Aug 5, 2025 Risk: low
  On August 5, 2025, MDxHealth SA announced the issuance of a press release, attached as Exhibit 99.1 to this Form 6-K filing. The press release details informati
• MDxHealth Appoints New Audit Committee Chair, Director Resigns — 6-K · Jul 3, 2025 Risk: low
  MDxHealth SA announced on July 3, 2024, that Michael Holder will join its Board of Directors as Chair of the Audit Committee, effective July 3, 2025. He will su
• MDxHealth SA Holds Shareholder Meetings — 6-K · Jun 6, 2025 Risk: low
  MDxHealth SA held its ordinary annual general shareholders' meeting (AGM) and an extraordinary general shareholders' meeting (EGM) on May 28, 2025. The agenda i
• MDxHealth SA Files 6-K, Incorporates Exhibits into F-3 — 6-K · May 14, 2025 Risk: low
  MDxHealth SA filed a Form 6-K on May 14, 2025, to report information as a foreign private issuer. The filing incorporates by reference Exhibit 99.1 into existin
• MDxHealth SA Announces General Shareholders' Meeting — 6-K · May 6, 2025 Risk: low
  MDxHealth SA is holding its Ordinary and Extraordinary General Shareholders' Meetings on May 28, 2025, in Ghent, Belgium. The company is a foreign private issue
• MDxHealth SA Schedules Shareholder Meeting for May 28 — 6-K · May 2, 2025 Risk: low
  MDxHealth SA is holding its Ordinary and Extraordinary General Shareholders' Meetings on May 28, 2025, in Ghent, Belgium. The company is a foreign private issue
• MDxHealth SA Files 2024 Annual Report — 20-F · Mar 31, 2025 Risk: medium
  MDxHealth SA filed its annual report on Form 20-F for the fiscal year ended December 31, 2024. The company, incorporated in Belgium, is listed under the SIC cod
• MDxHealth CEO Buys 50,000 Shares — 6-K · Mar 7, 2025 Risk: low
  On March 6, 2025, MDxHealth SA (NASDAQ: MDXH) announced that its CEO, Michael McGarrity, purchased 50,000 shares of the company's stock. McGarrity is also a mem
• MDxHealth SA Files 6-K, Attaches Press Release — 6-K · Feb 26, 2025 Risk: low
  On February 26, 2025, MDxHealth SA announced the issuance of a press release, attached as Exhibit 99.1 to this 6-K filing. The filing itself is a Report of Fore
• MDxHealth SA Files 6-K, Announces Press Release — 6-K · Jan 13, 2025 Risk: low
  On January 13, 2025, MDxHealth SA announced the issuance of a press release, attached as Exhibit 99.1 to this Form 6-K filing. The filing itself does not contai
• SC 13G Filing — SC 13G · Nov 14, 2024
• MDxHealth SA Files 6-K, Incorporates by Reference — 6-K · Nov 6, 2024 Risk: low
  MDxHealth SA filed a Form 6-K on November 6, 2024, for the month of November 2024. This report is for a foreign private issuer and is being incorporated by refe
• MDxHealth SA Files 6-K, Incorporates Exhibit 3.1 — 6-K · Oct 29, 2024 Risk: low
  MDxHealth SA filed a Form 6-K on October 29, 2024, to incorporate by reference Exhibit 3.1 into its existing Form F-3 registration statement (Registration State
• MVM Partners Amends 13D Filing for MDxHealth SA — SC 13D/A · Oct 28, 2024 Risk: medium
  MVM Partners, LLC, through its affiliates MVM GP (NO.5) LP and MVM V LP, has filed an amendment (No. 3) to its Schedule 13D for MDxHealth SA, dated October 28,
• SC 13G Filing — SC 13G · Oct 4, 2024
• SC 13G Filing — SC 13G · Oct 4, 2024
• MDxHealth SA Files 6-K, Incorporates Exhibits into F-3 — 6-K · Sep 30, 2024 Risk: low
  MDxHealth SA filed a Form 6-K on September 30, 2024, reporting information for the month of September 2024. The filing incorporates by reference several exhibit
• MDxHealth SA Files 6-K with Interim Report — 6-K · Aug 21, 2024 Risk: low
  MDxHealth SA filed a Form 6-K on August 21, 2024, reporting its 2024 Interim Report and a press release. The filing includes information for the month of August
• MDxHealth SA Reports Preliminary Q2 2024 Revenue of $22.2M — 6-K · Jul 8, 2024 Risk: medium
  MDxHealth SA reported preliminary Q2 2024 revenues of approximately $22.2 million and first half 2024 revenues of $42.0 million on July 8, 2024. The company's c
• MDxHealth SA Approves New Share Option Plan — 6-K · Jun 20, 2024 Risk: low
  MDxHealth SA held an extraordinary general shareholders' meeting on June 20, 2024, where they approved a new 2024 Share Option Plan and the issuance of 2,000,00
• MDxHealth SA Holds Shareholder Meetings — 6-K · Jun 5, 2024 Risk: low
  MDxHealth SA held its ordinary annual general shareholders' meeting (AGM) and an extraordinary general shareholders' meeting (EGM) on May 30, 2024. The agenda i
• MDxHealth SA Schedules May 30th Shareholder Meeting — 6-K · May 16, 2024 Risk: low
  MDxHealth SA is holding its Ordinary and Extraordinary General Shareholders' Meetings on May 30, 2024, in Ghent, Belgium. The company is a foreign private issue
• MDxHealth CEO Buys 45,000 Shares — 6-K · May 6, 2024 Risk: low
  On May 3, 2024, MDxHealth SA CEO Michael McGarrity purchased 45,000 shares of the company's common stock. This purchase was disclosed in a Form 6-K filing with
• MDxHealth SA Secures New Credit Facility — 6-K · May 1, 2024 Risk: medium
  On May 1, 2024, MDxHealth SA entered into a Credit Agreement where it acts as guarantor for its wholly-owned subsidiary, MDxHealth, Inc. The filing does not spe
• MDxHealth SA Files 2023 Annual Report on Form 20-F — 20-F · Apr 30, 2024 Risk: low
  MDxHealth SA (MDXH) filed a Foreign Annual Report (20-F) with the SEC on April 30, 2024. MDxHealth SA filed its annual report on Form 20-F for the fiscal year e
• MDxHealth SA Files 6-K Report with Press Release — 6-K · Mar 12, 2024 Risk: low
  On March 12, 2024, MDxHealth SA announced the issuance of a press release, attached as Exhibit 99.1 to this Form 6-K filing. The press release details informati
• MDxHealth SA Files 6-K Report for March 2024 — 6-K · Mar 6, 2024 Risk: low
  On March 6, 2024, MDxHealth SA announced the issuance of a press release, attached as Exhibit 99.1 to this 6-K filing. The press release details the company's a
• MDxHealth SA Furnishes Press Release via 6-K Filing — 6-K · Feb 16, 2024 Risk: low
  MDxHealth SA, a foreign private issuer, filed a Form 6-K on February 16, 2024, to furnish a press release issued on the same date. The company, based in Herstal
• SC 13G/A Filing — SC 13G/A · Feb 14, 2024
• MDxHealth Reports Preliminary Q4/FY23 Revenue, Issues 2024 Guidance — 6-K · Jan 8, 2024
  MDxHealth SA, a medical diagnostics company, filed a 6-K on January 8, 2024, to announce its preliminary fourth quarter and full year 2023 revenues and to provi

Risk Profile

Risk Assessment: Of MDXH's 29 recent filings, 0 were flagged as high-risk, 4 as medium-risk, and 25 as low-risk. The overall risk profile suggests relatively low risk with generally favorable filings.

Key Executives

• HARDISON DON M
• Michael Holder
• Regine Slagmulder
• Ron Kalfus
• Stijn Raes
• Michael McGarrity
• Eric Bednarski
• Scott Jones, Esq.

Industry Context

MDxHealth SA operates in the medical laboratories sector, focusing on diagnostic solutions.

Top Tags

foreign-private-issuer (13) · press-release (7) · 6-K (6) · shareholder-meeting (6) · corporate-governance (4) · sec-filing (4) · reporting (3) · interim-report (2) · registration-statement (2) · insider-buy (2)

Key Numbers

• Fiscal Year End: 2024 — The period covered by the annual report.
• Filing Date: March 31, 2025 — The date the 20-F was submitted to the SEC.
• Shares Purchased: 50,000 — CEO Michael McGarrity's recent stock acquisition.
• Commission File Number: 001-40996 — Identifies the company's filing with the SEC.
• Registration Statement Number: 333-268885 — Refers to the company's Form F-3 registration statement.
• Q2 2024 Preliminary Revenue: $22.2M — Indicates revenue generation for the second quarter.
• H1 2024 Preliminary Revenue: $42.0M — Shows revenue performance for the first half of the year.
• Cash Balance (June 30, 2024): $21.3M — Represents the company's liquidity at the end of Q2.
• Share Options: 2,000,000 — Approved under the new 2024 Share Option Plan
• Ordinary Shares Outstanding: 27,288,093 — As of December 31, 2023

Frequently Asked Questions